Health

AbbVie's Parkinson's drug shows promise in late-stage trial

Article Image

AbbVie (NYSE:ABBV) announced today positive results from a late-stage clinical trial evaluating its experimental drug, tavapadon, for the treatment of early Parkinson's disease.

The trial, which studied two doses of tavapadon as a monotherapy, demonstrated a statistically significant improvement in patients compared to placebo.

The improvement was measured using a rating scale that assesses various aspects of the disease.

Tavapadon, if approved, could offer a new treatment option for Parkinson's disease, a progressive neurological disorder characterized by tremors, stiffness, and difficulty walking.

The drug is being developed as a once-daily oral medication.

AbbVie acquired the rights to tavapadon through its $8.7 billion acquisition of Cerevel Therapeutics.

The positive results from this trial mark a significant milestone in the development of the drug and bring AbbVie closer to potentially offering a new treatment option for patients with Parkinson's disease.

Disclaimer
Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
Publisher
Grafa